OneDigital Investment Advisors LLC Takes $825,000 Position in Quest Diagnostics Incorporated $DGX

OneDigital Investment Advisors LLC purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,893 shares of the medical research company’s stock, valued at approximately $825,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Plato Investment Management Ltd acquired a new stake in Quest Diagnostics in the 2nd quarter valued at about $386,000. Bell Investment Advisors Inc acquired a new position in shares of Quest Diagnostics during the 2nd quarter worth approximately $66,000. Simplicity Wealth LLC acquired a new position in shares of Quest Diagnostics during the 2nd quarter worth approximately $4,702,000. HBK Sorce Advisory LLC purchased a new stake in shares of Quest Diagnostics in the second quarter valued at approximately $378,000. Finally, OMC Financial Services LTD acquired a new stake in shares of Quest Diagnostics in the second quarter valued at approximately $695,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Stock Performance

NYSE DGX opened at $236.71 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The company has a market cap of $26.13 billion, a P/E ratio of 25.13, a P/E/G ratio of 2.16 and a beta of 0.56. The stock has a 50-day moving average of $217.00 and a two-hundred day moving average of $204.06. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $240.13.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the prior year, the company earned $2.62 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio is 36.52%.

Insider Buying and Selling at Quest Diagnostics

In other news, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,747 shares of company stock valued at $3,947,088 in the last 90 days. Company insiders own 0.88% of the company’s stock.

Wall Street Analyst Weigh In

DGX has been the topic of a number of analyst reports. Barclays lifted their price objective on Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. Weiss Ratings upgraded Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday, August 12th. Mizuho boosted their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Truist Financial upped their price objective on shares of Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $235.31.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.